|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Table A6: Patient Baseline Characteristics, Matched, Unfavorable Risk, black men vs white men** | | | | | |
|  |  | **Black** | **White** | **p-value** | **SMD** |
|  |  | 2543 | 2543 |  |  |
| Treatment | EBRT+ADT | 883 (34.7) | 947 (37.2) | 0.099 | 0.06 |
|  | RP and PLND | 1470 (57.8) | 1394 (54.8) |  |  |
|  | EBRT+BT+ADT | 190 (7.5) | 202 (7.9) |  |  |
| Facility Type | Community Cancer Program | 201 (7.9) | 203 (8.0) | 0.775 | 0.03 |
|  | Comprehensive Community Cancer Program | 1153 (45.3) | 1166 (45.9) |  |  |
|  | Academic/Research Program | 911 (35.8) | 919 (36.1) |  |  |
|  | Integrated Network Cancer Program | 278 (10.9) | 255 (10.0) |  |  |
|  |  |  |  |  |  |
| Geography | New England | 106 (4.2) | 107 (4.2) | 0.235 | 0.091 |
|  | Middle Atlantic | 400 (15.7) | 425 (16.7) |  |  |
|  | South Atlantic | 761 (29.9) | 693 (27.3) |  |  |
|  | East North Central | 429 (16.9) | 477 (18.8) |  |  |
|  | East South Central | 252 (9.9) | 255 (10.0) |  |  |
|  | West North Central | 157 (6.2) | 181 (7.1) |  |  |
|  | West South Central | 169 (6.6) | 168 (6.6) |  |  |
|  | Mountain | 45 (1.8) | 36 (1.4) |  |  |
|  | Pacific | 224 (8.8) | 201 (7.9) |  |  |
|  |  |  |  |  |  |
| Insurance | Not Insured | 46 (1.8) | 40 (1.6) | 0.352 | 0.066 |
|  | Private Insurance | 1291 (50.8) | 1227 (48.3) |  |  |
|  | Medicaid | 51 (2.0) | 59 (2.3) |  |  |
|  | Medicare | 1076 (42.3) | 1119 (44.0) |  |  |
|  | Other Government | 43 (1.7) | 55 (2.2) |  |  |
|  | Insurance Status Unknown | 36 (1.4) | 43 (1.7) |  |  |
| Income | $38,000 - $47,999 | 678 (26.7) | 686 (27.0) | 0.713 | 0.041 |
|  | $48,000 - $62,999 | 662 (26.0) | 684 (26.9) |  |  |
|  | $63,000 + | 691 (27.2) | 651 (25.6) |  |  |
|  | < $38,000 | 498 (19.6) | 511 (20.1) |  |  |
|  | unknown | 14 (0.6) | 11 (0.4) |  |  |
| Charleson Deyo Comorbidity Index | 0 | 2141 (84.2) | 2126 (83.6) | 0.833 | 0.017 |
|  | 1 | 351 (13.8) | 366 (14.4) |  |  |
|  | 2 | 51 (2.0) | 51 (2.0) |  |  |
| Age |  | 64.01 (8.18) | 64.48 (8.16) | 0.043 | 0.057 |
| Risk Cohort | HR | 1994 (78.4) | 1968 (77.4) | 0.668 | 0.025 |
|  | IR | 341 (13.4) | 354 (13.9) |  |  |
|  | VHR | 208 (8.2) | 221 (8.7) |  |  |
| Diagnosis to treatment initiation time | 0-90 | 1895 (74.5) | 1886 (74.2) | 0.958 | 0.008 |
|  | >90 | 452 (17.8) | 459 (18.0) |  |  |
|  | unknown | 196 (7.7) | 198 (7.8) |  |  |
| clinical T stage | T1 | 1217 (47.9) | 1161 (45.7) | 0.297 | 0.069 |
|  | T2 | 681 (26.8) | 717 (28.2) |  |  |
|  | T3 | 413 (16.2) | 420 (16.5) |  |  |
|  | T4 | 14 (0.6) | 23 (0.9) |  |  |
|  | unknown | 3 (0.1) | 7 (0.3) |  |  |
|  | X | 215 (8.5) | 215 (8.5) |  |  |
| clinical Gleason score | <=6 | 62 (2.4) | 68 (2.7) | 0.876 | 0.038 |
|  | 10 | 13 (0.5) | 14 (0.6) |  |  |
|  | 7 | 497 (19.5) | 523 (20.6) |  |  |
|  | 8 | 396 (15.6) | 381 (15.0) |  |  |
|  | 9 | 194 (7.6) | 204 (8.0) |  |  |
|  | unknown | 1381 (54.3) | 1353 (53.2) |  |  |
| PSA | <10 | 776 (30.5) | 788 (31.0) | 0.891 | 0.022 |
|  | >20 | 1444 (56.8) | 1440 (56.6) |  |  |
|  | 10-20 | 258 (10.1) | 258 (10.1) |  |  |
|  | unknown | 65 (2.6) | 57 (2.2) |  |  |
| *Abbreviations: BT=brachytherapy; EBRT=external beam radiotherapy; RP=Radical Prostatectomy; PLND=pelvic lymph node dissection SMD=Standardized mean difference; CI=Confidence Interval* | | | | | |
| \*ng/ml | | | | | |
| \*\*combined gleason score | | | | | |